Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs
This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that address the full range of product requirements.
In response to the growing demand for peptide drugs, Cytovance Biologics and PolyPeptide have announced a partnership that combines Cytovance’s expertise in microbial and mammalian expression, process development and cGMP manufacturing with PolyPeptide’s capabilities in complex peptide development and manufacturing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113598664/en/
Axel Schleyer, CCO of Cytovance Biologics: “Cytovance has been supporting the development and scale-up of microbial and mammalian-expressed biologics for two decades. Combining our strengths with PolyPeptide’s is exactly what our customers and the industry need to support the rapidly advancing market demand.”
Trishul Shah, PolyPeptide Director of Business Development: “With a track record of over 1,000 therapeutic peptides manufactured, PolyPeptide offers deep peptide development and synthesis capabilities. The collaboration gives customers access to complementary technology portfolios to drive their innovative drug development projects.”
The two companies have partnered before on specific customer projects. The new collaboration broadens the partnership to the benefit of drug developers looking for additional capacity, fast ramp-up, and increased efficiency, helping to propel new peptide products to the clinic and the market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113598664/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip is One of the Top CPaaS Providers in Metrigy’s CPaaS MetriRank Report14.1.2025 10:43:00 CET | Press release
The reportshows Infobip's leadership in the CPaaS market for the second year running Global communications platformInfobiphas been ranked as the second-highest scoring Communications Platform as a Service (CPaaS) provider in analyst firm Metrigy’s latest CPaaS MetriRank Report. Infobip stands out for its stellar product mix and outstanding customer sentiment and customer business success scores, confirming its status as a CPaaS market leader. The 2024 MetriRank CPaaS report ranks the top players by market share in the global CPaaS market, comparing financials, market share momentum, product mix, customer sentiment, and customer business success. Infobip is recognized by Metrigy for its expanding go-to-market strategy, self-service capabilities and CPaaS ecosystem partnerships.Infobip scored maximum points for product mix, with a strong portfolio that includes not only a full range of communications APIs, but also CPaaS X, AI-powered omnichannel solutions, and other innovative offerings
Sodali & Co Appoints Andrew Benett as Chief Executive Officer14.1.2025 10:00:00 CET | Press release
Sodali & Co (the ‘firm’ or ‘Sodali’ and formerly Morrow Sodali), a leading global advisory firm, is pleased to announce the appointment of Andrew Benett as Chief Executive Officer, effective immediately. He will be based in New York. Andrew has a 30-year career across global advisory businesses including Global CEO and Chief Strategy Officer at Havas Creative Group, Chief Commercial Officer of Bloomberg Media and CEO and Executive Chair of Harte Hanks Inc., the NASDAQ-listed publishing company. Most recently, Andrew was a Partner at PwC working with clients to deliver organic and inorganic growth, as well as leading corporate strategy initiatives for the firm. He is an acknowledged strategist, author of three business books, and a fellow of the Aspen Institute. Andrew was appointed after a global search following Alvise Recchi stepping down as CEO last September. He joins the firm at an important moment in its development. In the last two years, Sodali has transformed at speed from a s
Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology14.1.2025 10:00:00 CET | Press release
Bioptimus announces a $76M funding milestone, with the latest injection of $41M led by Cathay Innovation less than 12 months from its initial seed roundSince the successful release of the largest AI foundation model for pathology in July, the company has been continuing its groundbreaking work and is now poised to release a breakthrough new multi-scale, multi-modal foundation model for biology in 2025The new model will allow the simulation of biology at unprecedented scale and dimension, creating biological innovation for medical, biotech, cosmetic industries, and beyond Bioptimus, the pioneering AI foundation model company, announced today that it has reached a significant funding milestone of $76 million. This total includes a $41 million cash injection, led by Cathay Innovation with participation from prominent investors, including Sofinnova Partners, Bpifrance through its Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, and ang
Cirium Ascend Consultancy Lands ‘Appraiser of the Year’ Title for the 10th Time14.1.2025 09:00:00 CET | Press release
2025 marks the third year in a row Cirium has been awarded the prestigious accolade, recognising their unparalleled expertise in the field Cirium Ascend Consultancy, part of the world’s most trusted source of aviation analytics, Cirium, has once again landed Airline Economics’ prestigious title of ‘Appraiser of the Year’ at an award ceremony last night. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113971776/en/ Cirium awarded 'Appraiser of the Year' (Photo: Business Wire) This marks the tenth win for Cirium Ascend Consultancy, demonstrating its unparalleled expertise within aviation consultancy and underlining its unwavering commitment to excellence, transparency and accuracy. The annual award was presented to Rob Morris, Global Head of Cirium Ascend Consultancy, at the Airline Economics Aviation 100 Global Leaders Awards 2025 in Dublin, Ireland, which celebrates the best companies, individuals and transactions in the a
Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth14.1.2025 07:00:00 CET | Press release
Almirall's unique dedication to medical dermatology and innovation - combined with its commercial excellence - fuel an era of sustained double-digit growth (net sales CAGR 2023-2030) and profitability enabling the company to reach more patients with relevant and impactful productsGrowth of Almirall’s psoriasis and atopic dermatitis franchises is anticipated to lead to over 800 million in annual peak sales in biologics, driven by Ebglyss® and Ilumetri®Strategic investments in commercial excellence, R&D and science leadership provide the basis for realising Almirall’s market potential as European leader in medical dermatology Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare Conference to provide an update on its business strategy and outlook. The company’s CEO and president Carlos Gallardo will highlight a new era for its business starting in 2025 – forecasting sustained double-digit growth of net sales (CAGR 202
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom